Skip to main content
XNCR logo

XNCR · Xencor Inc

Track XNCR — free
$35.40 -1.69 (-4.56%) At close · Nov 16
Market Cap
$2.66B
Shares
75.04M
Volume · Nov 16 1.03M Avg daily vol (3M) 1.55M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$35.40 Open$37.07 Day$35.34–37.39 52W close$10.41–39.97 Avg vol 30d1.7M Short int12.9M · 17.2% of shares · 6.6d Short vol49% Last earningsOct 26, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 4

Up next

Jul 22, 2027 Est · unconfirmed · in 35 wks
call held Feb 27, 2024

Latest documents

2026
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
XmAb819 delivered 45.5% confirmed response rate

XmAb819’s selected 400 mcg/kg IV dose produced five confirmed partial responses among 11 efficacy-evaluable patients, a 45.5% confirmed objective response rate. The Alexion settlement provides $105.0 million and ends U.S. Ultomiris royalties.

Revenue $116.52M ▲ 454.9% Net income $39.44M Diluted EPS $0.50
Read from the MD&A section
4 source passages
XmAb819 (ENPP3 x CD3): As of the October 1, 2026 data-cut, the efficacy-evaluable cohort at the 400 mcg/kg intravenous (IV) dose (n=11) reported five confirmed partial responses for a confirmed objective response rate of 45.5% per investigator assessment (RECIST v1.1), with one unconfirmed partial response for an unconfirmed objective response rate of 55%. Pursuant to the Settlement Agreement, we are entitled to receive aggregate consideration of $105.0 million from Alexion, payable in two equal installments of $52.5 million. Following the settlement, Alexion has no further obligation to pay royalties on U.S. sales of Ultomiris. Open the document at this passage
Nov 4
Current report 8-K
Third-quarter revenue $116.5 million, net income $39.4 million

Xencor reported third-quarter revenue of $116.5 million and net income of $39.4 million, versus $21.0 million revenue and a $6.0 million net loss in 2025. It held $555.7 million in cash, cash equivalents and marketable debt securities.

Financial results
3 source passages
Revenue for the third quarter ended September 30, 2026 was $116.5 million, compared to $21.0 million for the same period in 2025. Net income attributable to Xencor for the third quarter ended September 30, 2026 was $39.4 million, or $0.50 on a fully diluted per share basis, compared to a net loss of $6.0 million, or $(0.08) on a fully diluted per share basis, for the same period in 2025. Cash, cash equivalents and marketable debt securities totaled $555.7 million as of September 30, 2026, compared to $610.8 million as of December 31, 2025. Open the document at this passage
Oct 26
Current report 8-K Events of Oct 25
Financial results, Regulation FD disclosure, Other events

Xencor selected 400 mcg/kg for XmAb819 as the proposed intravenous RP3D after reporting 45.5% cORR, 55% uORR and an 82% 6-month PFS Kaplan-Meier estimate. It plans to discuss a potential accelerated approval pathway with the FDA in 1H2027.

Read from the first part of this long document
Aug 5
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $51.22M ▲ 17.5% Net loss $21.73M Diluted EPS -$0.29
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$200.49M
Trailing 12 months
Net income (TTM)
−$117.65M
Trailing 12 months
Revenue growth YoY
+454.9%
Year over year
Operating margin
-72.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-6.6%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$35.44M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+5.3%
Year over year · more shares
Price change (1Y)
+137.1%
Trailing year
Short interest
17.2%
Latest settlement · 6.6 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Bearish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +94%
above
Price vs 50-day avg +29%
above
RSI (14) 62
neutral
MACD trend Positive
52-week position 85%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +53%
trailing
6-month return +202%
trailing
YTD return +131%
this year
Relative strength +203%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $28 › 200d $18 — 50d above 200d
Institutional flow Distributing
-1% holders QoQ · +39 funds added
Insider flow Distributing
Net -$3.6M over 90 days · 100% sells
Short interest Rising
17.19% of shares out · ▲ +5.1% MoM · 6.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
205 holders — near 3-yr high, broad support
Squeeze score 81
high risk · 0–100
Fundamentals
Fair
Revenue growth +14%
Y/Y
EPS growth +65%
Y/Y
Free cash flow $-138.3M
Balance sheet $65.7M
net debt
Quant / Vol
risk profile
Very High
Volatility 65%
annualized · 1-yr
Max drawdown −43%
past year
ATR 5.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Aug 5, 2026
Cash, cash equivalents and marketable debt securities · end of 2026 $420M – $440M
Previous outlook earlier release · from the 8-K filed May 6, 2026

Still-open targets the latest release did not restate under the same label.

Cash, cash equivalents and marketable debt securities · end 2026 $380M – $400M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+94% Bullish
Price vs 50-day avg
+29% Bullish
RSI (14)
62 Neutral
MACD trend
Positive Bullish
52-week position
85% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross) No cross
50d $28 › 200d $18 — 50d above 200d
Institutional flow Distributing
-1% holders QoQ · +39 funds added
Insider flow Distributing
Net -$3.6M over 90 days · 100% sells
Short interest Rising
17.19% of shares out · ▲ +5.1% MoM · 6.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
205 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $10 Now $35 · 85% Range high $40
vs 200-day avg +94% vs 50-day avg +29%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
XNCR
Xencor Inc
this stock
$2.66B +131.2% +13.7% — 17.2%
VRTX
Vertex Pharmaceuticals Inc
$136.35B +18.6% +46.2% 34.6 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$98.52B +23.4% +20.8% 21.1 2.1%
MRNA
Moderna, Inc.
$87.10B +630.0% +4.3% — 8.2%
CSLLY
Csl Ltd
$65.26B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
205
% held
77.7%
Net QoQ
-25.9M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
248
View
Short & Settlement
Short Interest Rising
Shares short
12.9M
Days to cover
6.6d
Change
+629.9K sh
View
Short Volume
Short vol %
49%
As of
Nov 16, 2026
Short Total
View
Fails to Deliver
FTD shares
2.3K
Value
$69.7K
As of
Oct 28, 2026
View
Off-Exchange
Off-exchange %
42.4%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$3.6M
Buyers / Sellers
0 / 2
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$125.6M
Net income (FY)
$-91.9M
EPS diluted
$-1.24
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 4, 2026
This year
21

XmAb819’s selected 400 mcg/kg IV dose produced five confirmed partial responses among 11 efficacy-evaluable patients, a 45.5% confirmed objective response rate. The Alexion settlement provides $105.0 million and ends U.S. Ultomiris royalties.

View
Proposed Sales
Value
$402.2K
Shares
10.1K
Filed
Nov 12, 2026
View
Exempt Offerings
Offering
$25.0M
Filed
Nov 19, 2021
View
Earnings & Events
Webcasts
Last webcast
Oct 26, 2026
View
Investor Relations
Latest news
Xencor Presents Initial Plamotama…
Published
Nov 9, 2026
View

Performance

5D 20D 120D MTD YTD
XNCR -8.3% +52.7% +202.1% +18.7% +131.2%
SPY -1.7% -3.5% -1.4% -2.1% +8.5%
vs SPY -6.6% +56.1% +203.5% +20.8% +122.7%
Key facts CIK 1326732 CUSIP 98401F105 13F (30d) 205 filings 189 filers Visit website Investor relations